This listing has been removed


We're sorry, but this listing is not available anymore. Here is a list of alternative listings.

Qiagen Retsch MM300 Tissuelys


Availability: listing already sold

Listing description

This Qiagen Retsch MM300 TissueLyser is in excellent condition.
The QIAGEN TissueLyser provides rapid and efficient disruption of cells and tissues for the BioRobot. Processing of up to 2 x 96 samples takes as little as 2 - 4 minutes. Disruption is achieved through the beating and grinding effect of beads on the sample material as they are shaken with the sample in a variety of grinding vessels. The optimized design of TissueLyser Adapter Sets ensures that tubes remain securely sealed during disruption. This prevents cross-contamination, which is especially important for highly sensitive downstream applications, such as real-time RT-PCR or microarray analysis.

This equipment is located in US


Please note that this description may have been translated automatically.

Availability: listing already sold

Listing information

Manufacturer Qiagen Retsch
Model MM300 Tissuelys
Year -
Country USA USA
Condition Good
Main category Lab, Medical and Bioscience
Subcategory Analytical Lab
ID P70914005

Availability: listing already sold

About the seller

Client type Machinery dealer
On Kitmondo since 2011
Number of listings 35
Country USA USA
Employees 11 - 50
Established 2007
Company description

We are dedicated to supporting researchers with high-quality, pre-owned instruments at affordable cost, along with expert service and support. While specializing in ion chromatography systems, gas… read more

We are dedicated to supporting researchers with high-quality, pre-owned instruments at affordable cost, along with expert service and support. While specializing in ion chromatography systems, gas chromatographs, liquid chromatography equipment, mass spectrometers (GCMS Systems, LCMS Systems), and microplate readers, we also offer a wide range of laboratory instruments in all other fields.

Last activity April 18, 2024